<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: RAD51D and RAD54L are involved in homologous recombination, and rare mutations in RAD51D were recently found in breast-<z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> families </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated RAD51D and RAD54L for mutations in breast and <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> patients in the Finnish population </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The study sequenced the RAD51D and RAD54L genes in 95 breast and/or <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> families and genotyped the identified mutation in an additional 2200 breast and 553 ovarian <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients and 2102 population controls </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate the role of the mutation in other common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, 1094 prostate and 980 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients were genotyped </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In the screening of RAD51D, one deleterious <z:e sem="disease" ids="C0263541" disease_type="Disease or Syndrome" abbrv="">founder</z:e> mutation c.576+1G&gt;A was identified in two breast-<z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> families </plain></SENT>
<SENT sid="5" pm="."><plain>No mutations were found in RAD54L </plain></SENT>
<SENT sid="6" pm="."><plain>Altogether, the c.576+1G&gt;A mutation was detected in 5/707 patients with a personal or family history of <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> (OR 9.16, 95% CI 1.07 to 78.56; p=0.024), with the highest frequency among breast-<z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> families (3/105 vs 1/1287 controls, OR 37.82, 95% CI 3.90 to 366.91; p=0.0016), but no elevated frequency among <z:hpo ids='HP_0003002'>breast cancer</z:hpo> patients/families (2/2105, p=1) </plain></SENT>
<SENT sid="7" pm="."><plain>The mutation was not found among prostate or <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The results of this study on familial and unselected breast, ovarian, colorectal, and <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> patients suggest that RAD51D is primarily a moderate penetrance susceptibility gene for <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>, with clinical significance for the carriers </plain></SENT>
</text></document>